Abstract: An intermediate of biliverdin represented by formula 1, and preparation method and use thereof: in formula 1, R is C1-C5 alkyl, or benzyl; “” at positions A and B independently represent a single bond or a double bond; when “” represents a single bond, R1 or R2 connected to the single bond is selected from one of tosyl, p-toluenesulfonyl, phenylsulfonyl, phenylsulfinyl; and when “” represents a double bond, R1 or R2 connected to the double bond is hydrogen.

Abstract: A compound having the formula (LA)mIr(LB)3-m, where LA is and LB is is disclosed. In the formula (LA)mIr(LB)3-m, LA and LB are different; each of X1 to X5 is C—RF or nitrogen; X is selected from O, S, and Se; each R1, R2, RB, RD, and RF is hydrogen or a substituent; R3 is alkyl, cycloalkyl, or a combination thereof; and m is 1 or 2. OLEDs, consumer products, and formulations including the compound are also disclosed.

Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein R2, R3, R5, R6, R7, and R8 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.

Abstract: The compound 3,4-dihydroquinazoline sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate of formula (I) is particularly useful for treatment and prevention of diseases associated with members of the herpes viridae group, including cytomegalovirus (CMV), particularly human cytomegalovirus (HCMV). The compound can be prepared from a suspension of sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate in diisopropylether, or from a solution of sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate in methylene chloride.

Abstract: The present disclosure provides metabolites of belumosudil and uses of the metabolites in of treating patients with ROCK2-mediated diseases including cGVHD.

Abstract: The present invention relates to a salt of (6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidine-1-yl)methanone (herein referred to as “compound A”), a solid form of the salt, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and uses of the solid form as a Rho-associated protein kinase (ROCK) inhibitor, preferably a selective ROCK2 inhibitor.

Abstract: A novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising the compound and a pharmaceutically acceptable salt thereof. The use of the compound and the composition in the prevention or treatment of diseases related to arginine vasopressin Vla receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system. A method for preventing and/or treating arginine vasopressin-related diseases.

Abstract: Disclosed are compounds according to formula I: and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods of improving platelet survival upon transfusion with one or more compounds or compositions as described herein.

Abstract: The invention relates to a new group of aromatic sulphonamides derivatives of formula (I) and their synthesis and use for modulation of the activity of protein disulfide isomerase (PDI). More particularly, the invention provides small molecule inhibitors of PDI A3 that display antiplatelet, antithrombotic and anticancer activities.

Abstract: Provided herein are compounds, in particular, Compound 1, and compositions useful for treating or preventing diseases or disorders that are modulated by thyroid hormone receptor agonists, such as non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD).

Abstract: Pyrazole carboxylate ester compounds have a structural formula of formula (I): Q is Q1 or Q3 The pyrazole carboxylate ester compounds has herbicidal activity and can be used for controlling weeds.

Abstract: The present disclosure relates to the compound trans-4-[1-(3-chlorophenyl)-7-methoxy-2,4-dioxo-pyrimido[5,4-c]quinolin-3-yl]cyclohexanecarboxylic acid, pharmaceutically acceptable salts, and use thereof as a therapeutic agent including treatment of inflammatory disorders.

Abstract: The invention relates to a combination comprising a carotenoid, a carotenoid metabolite, a carotenoid derivative, analogue or an ester or salt thereof and a second component selected from the group consisting of an inhibitor of one or more members of the BCL-2 anti-apoptotic protein family, an activator of pro-apoptotic BCL-2 family members, a senolytic agent and a senomorphic agent. The invention also relates to a food, a cosmeceutical, a nutraceutical, a cosmetic or pharmaceutical composition comprising the combination of the invention and its use in a cosmetic method and it medical uses.

Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII: or a Pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases, particularly in plants.

Abstract: The present disclosure relates to a compound having an AhR inhibitory effect as shown in FIG. (I), and a use thereof and a preparation method thereof.

Abstract: Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise-induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Abstract: Disclosed are bifunctional compounds (degraders) that target FAK or FAK and ALK for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.

Abstract: The present disclosures provides surprising insight into new technologies for treatment and/or prevention of certain types of hair loss (also known as alopecia), including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia. Among other things, the present disclosure provides surprising insight that plasminogen activator inhibitor-1 (PAI-1) inhibitors may be surprisingly effective and/or useful in the treatment and/or prevention of certain types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia. Furthermore, the present disclosure provides insight that provided new technologies may not be particularly effective and/or useful in the treatment and/or prevention of other types of alopecia such as radiation-induced alopecia, chemotherapy-induced alopecia, and alopecia due to chronic discoid lupus erythematosus.